# Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus

> **NCT02935673** · PHASE2 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 49 (actual)

## Conditions studied

- Respiratory Syncytial Viruses

## Interventions

- **DRUG:** lumicitabine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02935673
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-25
- **Primary completion:** 2018-07-17
- **Final completion:** 2018-07-17
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** sponsor decision
- **Last updated:** 2019-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02935673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02935673, "Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02935673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*